JAFRON(300529)2024-04-25 12:05Financial Performance - The company's operating revenue for 2023 was ¥1,922,348,169.84, a decrease of 22.84% compared to the adjusted revenue of ¥2,491,439,432.10 in 2022[44]. - The net profit attributable to shareholders for 2023 was ¥436,492,212.29, reflecting a significant decline of 50.93% from the adjusted net profit of ¥889,564,381.85 in 2022[44]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥409,043,029.02, down 50.27% from the adjusted figure of ¥822,471,213.39 in 2022[44]. - The basic earnings per share for 2023 was ¥0.55, a decrease of 50.89% compared to ¥1.12 in 2022[44]. - The diluted earnings per share for 2023 was ¥0.57, down 49.56% from ¥1.13 in 2022[44]. - The weighted average return on equity for 2023 was 13.09%, a decline of 13.16% from 26.25% in 2022[44]. - The decline in performance was primarily due to industry demand shrinkage, policy adjustments, and intensified competition[149]. Cash Flow and Assets - Total cash inflow from operating activities decreased by 17.71% to ¥2,523,492,517.54 in 2023 from ¥3,066,622,585.13 in 2022[4]. - Net cash flow from operating activities increased by 3.73% to ¥916,743,866.89 in 2023 compared to ¥883,800,425.82 in 2022[4]. - Total cash outflow from investment activities decreased significantly by 89.62% to ¥262,253,333.78 in 2023 from ¥2,526,071,169.97 in 2022[4]. - Cash and cash equivalents increased by 1.54% to ¥215,194,652.03 in 2023 from ¥211,929,120.23 in 2022[4]. - The company's cash and cash equivalents accounted for 50.70% of total assets at the end of 2023, up from 47.24% at the beginning of the year[7]. - The total assets at the end of 2023 amounted to ¥5,543,301,641.00, representing a 2.34% increase from ¥5,416,542,817.13 at the end of 2022[44]. Investments and Projects - The company invested a total of ¥103,919,698.41 in blood purification product capacity expansion projects during the reporting period[12]. - The revenue from the Hubei Jianfan Hemodialysis Powder Liquid Product Production Base Project was ¥40,869,400 in 2023[18]. - The company plans to actively promote operational management to ensure the expected benefits of the project are realized in the future[18]. Research and Development - The company is increasing R&D investment in products that meet market demand to promote sustainable business development[23]. - The company will increase R&D investment to lead industry development and enhance core competitiveness[52]. - The company is committed to increasing its R&D capabilities by optimizing existing products and developing new generation products[178]. Shareholder Returns and Dividends - The company is committed to improving shareholder returns through active dividends and share buybacks[52]. - The company plans to distribute a cash dividend of 4.00 RMB per 10 shares (including tax), totaling approximately 309.79 million RMB based on a total share count of 774,466,316 shares after accounting for repurchased shares[77]. - The board believes the profit distribution plan aligns with the company's actual situation and supports sustainable development while providing returns to investors[77]. - The company completed the distribution of cash dividends of 6.70 RMB per 10 shares for the 2022 fiscal year, amounting to approximately 535.24 million RMB[103]. Corporate Governance - The board of directors and supervisory board underwent a reshuffle on April 21, 2023, with several members leaving and new members being elected[59]. - The company emphasizes the importance of stock incentive plans to enhance the responsibility and mission of the management team and core staff[74]. - The independent directors fulfilled their duties and played their expected roles during the reporting period[76]. - The company has ensured that minority shareholders had sufficient opportunities to express their opinions and that their legal rights were adequately protected[76]. - The company’s financial and operational activities were effectively supervised by the board of directors, who regularly monitored the company's performance[71]. Market Strategy and Compliance - The company is focusing on expanding its domestic blood purification market while actively exploring international markets to drive future performance growth[178]. - The company is enhancing its compliance framework to support long-term development amidst improving external operating environments and healthcare policy optimizations[178]. - The company is closely monitoring changes in industry regulations and is prepared to adjust its operational strategies to mitigate risks associated with regulatory changes[23]. Employee Stock Ownership Plans - The company has completed the stock purchases under both employee stock ownership plans, which will be locked according to regulations[114]. - The company held its first temporary shareholders' meeting on June 19, 2023, to approve the employee stock ownership plan and its management measures[110]. - The management committee for the second employee stock ownership plan was established and elected on June 27, 2023[110]. - The company’s independent directors provided independent opinions on the relevant matters regarding the stock repurchase and employee stock ownership plans[108]. Operational Efficiency and Internal Control - The company has implemented a comprehensive upgrade in training programs, focusing on enhancing management skills and operational efficiency[102]. - The company is implementing internal reforms to enhance operational efficiency and management levels, including organizational structure adjustments and performance evaluation reforms[178]. - The company is committed to improving its internal control systems and has established an audit committee to oversee internal audits[88]. - The company has reported zero significant non-financial control deficiencies during the reporting period[91]. - The company has no significant internal control deficiencies reported during the reporting period[141].